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1. INTRODUCTION {#mgg3801-sec-0005}
===============

Obstructive sleep apnea (OSA), characterized by repetitive episodes of shallow or paused breathing during sleep despite the effort to breathe, is a highly prevalent sleep disorder which increases health risks such as cardiovascular disease, stroke, aortic disease, metabolic syndrome, diabetes, and depression (Jehan et al., [2018](#mgg3801-bib-0013){ref-type="ref"}; Mohammad et al., [2019](#mgg3801-bib-0023){ref-type="ref"}; Peres et al., [2019](#mgg3801-bib-0027){ref-type="ref"}; Smith & Amin, [2019](#mgg3801-bib-0031){ref-type="ref"}; Takagi & Umemoto, [2016](#mgg3801-bib-0034){ref-type="ref"}; Wanderer & Rathmell, [2019](#mgg3801-bib-0037){ref-type="ref"}; Wang et al., [2019](#mgg3801-bib-0038){ref-type="ref"}). It was estimated that 13 million people in China suffered from OSA (Young, [2004](#mgg3801-bib-0044){ref-type="ref"}). OSA with excessive daytime sleepiness (EDS) occurred in 6% (range, 3%--18%) of men and in 4% (range, 1%--17%) of women (Franklin & Lindberg, [2015](#mgg3801-bib-0011){ref-type="ref"}). EDS can have a serious impact on an individual\'s health, safety, and quality of life (Young, [2004](#mgg3801-bib-0044){ref-type="ref"}).

OSA is a complex disease that is affected by multiple factors, including genetic factors and environmental exposures (Sun, Hu, Tu, Zhong, & Xu, [2015](#mgg3801-bib-0033){ref-type="ref"}). Previous studies have identified higher levels of inflammatory biomarkers contributed to poor sleep, although some results were inconsistent (Canto Gde et al., [2015](#mgg3801-bib-0004){ref-type="ref"}; Hirsch, Evans, Wong, Machaalani, & Waters, [2018](#mgg3801-bib-0012){ref-type="ref"}; Nowakowski, Matthews, von Kanel, Hall, & Thurston, [2018](#mgg3801-bib-0026){ref-type="ref"}; Sun et al., [2015](#mgg3801-bib-0033){ref-type="ref"}). Among them, *interleukin‐6* (*IL‐6*, OMIM: 147620), *tumor necrosis factor* (*TNF*, OMIM: 191160), *C Reactive Protein* (*CRP*, OMIM: 123260), and *von Willebrand factor* (*VWF*, OMIM: 613160) antigen were the most frequently assessed inflammatory biomarkers (Canto Gde et al., [2015](#mgg3801-bib-0004){ref-type="ref"}; Hirsch et al., [2018](#mgg3801-bib-0012){ref-type="ref"}; Nowakowski et al., [2018](#mgg3801-bib-0026){ref-type="ref"}; Sun et al., [2015](#mgg3801-bib-0033){ref-type="ref"}). These findings underscore the important role of inflammatory profile for sleep problems and overall health. Meanwhile, epidemiological studies to date have identified strong associations between genetic variants of some candidate genes and susceptibility of OSA, although further research is needed (Sun et al., [2015](#mgg3801-bib-0033){ref-type="ref"}).

In current study, we hypothesized that *VWF* Thr789Ala (rs1063856), *IL‐6* −572G/C (rs1800796), *TNF* −308G/A (rs1800629), and *CRP* −717A \> G (rs2794521) would be associated with elevated serum levels of corresponding inflammatory biomarkers, then caused the occurrence of OSA and influenced the severity of OSA. We hope these stable genetic biomarkers could explain the variability in the relationship between susceptibility of OSA and levels of these inflammatory biomarkers.

2. PATIENTS AND METHODS {#mgg3801-sec-0006}
=======================

2.1. Ethical compliance {#mgg3801-sec-0007}
-----------------------

This study was approved by the Institutional Review Board for Zhoupu hospital, and written informed consent was obtained from all participants.

2.2. Study population {#mgg3801-sec-0008}
---------------------

Consecutive patients with suspected OSA who were undergoing polysomnography (PSG) test in Affiliated Zhoupu Hospital of Shanghai University of medicine and health science were invited to participate in this study. All the subjects underwent an overnight laboratory‐based PSG, and measured the apnea--hypopnea index (AHI). OSA was defined as an AHI \> 5 events/hr, and daytime symptoms specific for an OSA syndrome. For the severity of OSAs, patients were grouped according to the following classification by American Academy of Sleep Medicine (AASM 2007): mild group (AHI: 5--15 events/hr), moderate group (AHI: 15--30 events/hr), and severe group (AHI \> 30 events/hr). AHI \< 5 events/hr was diagnosed as healthy subjects. A total of 750 patients with OSA and 800 healthy controls matched for age, gender, and ethnicity were included in this study. Within 20 min of awakening, 5 ml of peripheral blood was drawn from each patient in EDTA‐containing tubes and stored at −80°C.

2.3. DNA extraction and genotyping {#mgg3801-sec-0009}
----------------------------------

Genomic DNA was extracted from the whole blood by DNA isolation kit (Tiangen, Beijing, China), according to the manufacturer\'s protocol. The purity and concentration of DNA were measured by a nanodrop spectrophotometer (Thermo Scientific, Waltham, MA, USA), with absorbance rations from 1.8 to 2.0 at the length of A260/A280. Genotyping of *VWF* rs1063856, *IL‐6* rs1800796, *TNF* rs1800629, and *CRP* rs2794521 were determined using TaqMan single nucleotide polymorphism (SNP) genotyping technique on an ABI PRISM® 7900HT Fast Real--Time PCR System (Applied Biosystems). Ten percent of the DNA samples were selected randomly for further validation, with a consistency of 100%.

2.4. Statistical analysis {#mgg3801-sec-0010}
-------------------------

All data analyses were performed with SPSS (version 22.0) statistical software (Chicago, IL). Statistical significance was accepted at a level of *p* \< 0.05. Deviation from the Hardy--Weinberg equilibrium was assessed using a chi‐squared test with one degree of freedom. Statistical significance for categorical variables was assessed by the chi‐squared or Fisher\'s exact test. The OSA risk and severity associated with the candidate SNPs were estimated by computing the odds ratios (ORs) and their 95% confidence intervals (CIs) by logistic regression analysis, adjusting for age, gender, and BMI. The analyses were done first per allele (allelic model) and then per genotype (additive model).

3. RESULTS {#mgg3801-sec-0011}
==========

3.1. Demographic, clinical, and anthropometric profiles {#mgg3801-sec-0012}
-------------------------------------------------------

As shown in Table [1](#mgg3801-tbl-0001){ref-type="table"}, the main demographic and clinical characteristics of the 750 OSA cases and 800 healthy controls were presented. There were no significant differences between the OSA cases and control groups in age and gender (*p* \> 0.05), which indicated the successful matching. The OSA cases had significantly larger percentages of high BMI than controls (*p* \< 0.001), which means high BMI was a risk factor for development of OSA. Patients with OSA were divided into 194 (25.9%) mild patients, 200 (26.6%) moderate patients, and 356 (47.5%) severe patients according to their AHI value.

###### 

Distributions of selected variables in OSA cases and healthy controls

                    Cases (*n* = 750)   Controls (*n* = 800)   *p* value
  ----------------- ------------------- ---------------------- -----------
  Age                                                           
  \<50              361 (48.1%)         384 (48.0%)            0.958
  ≥50               389 (51.9%)         416 (52.0%)             
  Gender                                                        
  Male              629 (83.9%)         655 (81.9%)            0.299
  Female            121 (16.1%)         145 (18.1%)             
  BMI (kg/m^2^)                                                 
  \<25              89 (11.9%)          367 (45.9%)            \<0.001
  ≥25               661 (88.1%)         433 (54.1%)             
  Severity of OSA                                               
  Mild              194 (25.9%)                                 
  Moderate          200 (26.6%)                                 
  Severe            356 (47.5%)                                 
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3.2. Associations of candidate SNPs with susceptibility of OSA {#mgg3801-sec-0013}
--------------------------------------------------------------

As shown in Table [2](#mgg3801-tbl-0002){ref-type="table"}, all four functional inflammatory SNPs (*VWF* rs1063856, *IL‐6* rs1800796, *TNF* rs1800629, and *CRP* rs2794521) were genotyped, and the genotypic distribution of the four functional SNPs in the healthy controls met the Hardy--Weinberg equilibrium (*p* \> 0.05). We found the minor alleles of *VWF* rs1063856 (OR = 1.50, 95% CIs = 1.10--2.04; *p* = 0.010), *IL‐6* rs1800796 (OR = 1.32, 95% CIs = 1.11--1.56; *p* = 0.002), *TNF* rs1800629 (OR = 1.44, 95% CIs = 1.13--1.83; *p* = 0.003), and *CRP* rs2794521 (OR = 1.27, 95% CIs = 1.04--1.55; *p* = 0.021) were all significantly associated with increased susceptibility of OSA, compared with their major alleles. The associations kept robust even after Bonferroni adjustment for *VWF* rs1063856, IL‐6 rs1800796, and *TNF* rs1800629.

###### 

Associations of candidate SNPs with susceptibility of OSA

  Genotype           Cases   Controls   Adjusted OR (95% CI)[a](#mgg3801-note-0002){ref-type="fn"}   *p* Value
  ------------------ ------- ---------- ------------------------------------------------------------ -----------
  *VWF* rs1063856                                                                                     
  AA                 650     720        1.00 (reference)                                              
  AG                 89      76         1.35 (0.95--1.92)                                            0.098
  GG                 11      4          3.17 (1.08--9.32)                                            0.036
  G versus A                            1.5 (1.1--2.04)                                              0.010
  *IL‐6* rs1800796                                                                                    
  GG                 327     409        1.00 (reference)                                              
  CG                 351     334        1.37 (1.09--1.72)                                            0.007
  CC                 72      57         1.64 (1.11--2.42)                                            0.012
  C versus G                            1.32 (1.11--1.56)                                            0.002
  *TNF* rs1800629                                                                                     
  GG                 576     656        1.00 (reference)                                              
  AG                 153     132        1.37 (1.04--1.82)                                            0.027
  AA                 21      12         2.07 (1.02--4.22)                                            0.044
  A versus G                            1.44 (1.13--1.83)                                            0.003
  *CRP* rs2794521                                                                                     
  AA                 471     541        1.00 (reference)                                              
  AG                 237     226        1.25 (0.97--1.61)                                            0.082
  GG                 42      33         1.52 (0.93--2.49)                                            0.097
  G versus A                            1.27 (1.04--1.55)                                            0.021

Adjusted for age, gender, and BMI.

John Wiley & Sons, Ltd

3.3. Associations of candidate SNPs with severity of OSA {#mgg3801-sec-0014}
--------------------------------------------------------

All four inflammatory SNPs were observed in the different severity of OSA patients groups, and the severe OSA cases were compared with the mild and moderate OSA (Table [3](#mgg3801-tbl-0003){ref-type="table"}). Among them, minor alleles of *VWF* rs1063856 (OR = 1.75, 95% CIs = 1.18--2.62; *p* = 0.006), IL‐6 rs1800796 (OR = 1.39, 95% CIs = 1.10--1.76; *p* = 0.006) were associated with the severity of OSA.

###### 

Associations of candidate SNPs with severity of OSA

  Genotype             Severe   Mild and moderate   Adjusted OR (95% CI)[a](#mgg3801-note-0003){ref-type="fn"}   *p* Value
  -------------------- -------- ------------------- ------------------------------------------------------------ -----------
  *VWF* rs1063856                                                                                                 
  AA                   298      352                 1.00 (reference)                                              
  AG                   50       39                  1.57 (0.99--2.5)                                             0.055
  GG                   8        3                   3.28 (0.94--11.44)                                           0.063
  G versus A                                        1.75 (1.18--2.62)                                            0.006
  *IL‐6* rs1800796                                                                                                
  GG                   138      189                 1.00 (reference)                                              
  CG                   177      174                 1.45 (1.05--2)                                               0.024
  CC                   41       31                  1.88 (1.12--3.17)                                            0.017
  C versus G                                        1.39 (1.1--1.76)                                             0.006
  *TNFTNF* rs1800629                                                                                              
  GG                   275      301                 1.00 (reference)                                              
  AG                   72       81                  1.01 (0.87--1.17)                                            0.874
  AA                   9        12                  0.85 (0.44--1.67)                                            0.644
  A versus G                                        0.98 (0.88--1.08)                                            0.680
  *CRP* rs2794521                                                                                                 
  AA                   220      251                 1.00 (reference)                                              
  AG                   115      122                 1.12 (0.71--1.77)                                            0.632
  GG                   21       21                  1.19 (0.54--2.59)                                            0.668
  G versus A                                        1.12 (0.78--1.61)                                            0.540

Adjusted for age, gender, and BMI
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4. DISCUSSION {#mgg3801-sec-0015}
=============

The current study explored associations between four functional inflammatory SNPs (*VWF* rs1063856, IL‐6 rs1800796, *TNF* rs1800629, and *CRP* rs2794521) with the susceptibility, as well as severity of OSA in a large case--control study in Chinese population. We found all four functional SNPs were significantly associated with increased susceptibility of OSA, and minor alleles of *VWF* rs1063856 and *IL‐6* rs1800796 were associated with the increased severity of OSA. These findings further confirmed the crucial role of inflammatory biomarkers in the occurrence and development of sleep disorder.

Meta‐analyses revealed that inflammatory cytokines were closely related to the occurrence and development of OSA (Li & Zheng, [2017](#mgg3801-bib-0020){ref-type="ref"}; Nadeem et al., [2013](#mgg3801-bib-0025){ref-type="ref"}). Among them, *VWF*, which encodes a glycoprotein involved in hemostasis, could cause lower sleep efficiency (*b*/*SE* = 0.02/0.08), *p* = 0.002) (Nowakowski et al., [2018](#mgg3801-bib-0026){ref-type="ref"}). Measures of sleep fragmentation were also related to *VWF* (von Kanel et al., [2007](#mgg3801-bib-0036){ref-type="ref"}). *VWF* rs1063856 was first associated with higher *VWF* levels and myocardial infarction risk in patients with Type I diabetes (Lacquemant et al., [2000](#mgg3801-bib-0018){ref-type="ref"}). Then, it was found to influence plasma levels of FVIII and modify *VWF* biosynthesis and clearance (Mufti et al., [2018](#mgg3801-bib-0024){ref-type="ref"}; Smith et al., [2010](#mgg3801-bib-0032){ref-type="ref"}). Fernandez‐Cadenas et al. ([2012](#mgg3801-bib-0009){ref-type="ref"}) found *VWF* rs1063856 was associated with fibrinolytic early recanalization in patients with ischemic stroke. However, none of the studies have evaluated the association of *VWF* rs1063856 with OSA. In the current study, we first identified *VWF* rs1063856 was not only associated with the susceptibility, but also with the severity of OSA.

*IL‐6* was the most focused inflammatory biomarker for OSA (Chu & Li, [2013](#mgg3801-bib-0005){ref-type="ref"}; Kaditis et al., [2014](#mgg3801-bib-0014){ref-type="ref"}; Kurt, Tosun, & Talay, [2013](#mgg3801-bib-0017){ref-type="ref"}; Lopez‐Pascual et al., [2017](#mgg3801-bib-0022){ref-type="ref"}; Popko et al., [2008](#mgg3801-bib-0029){ref-type="ref"}; Shalitin, Deutsch, & Tauman, [2018](#mgg3801-bib-0030){ref-type="ref"}; Wu et al., [2016](#mgg3801-bib-0042){ref-type="ref"}; Zhong, Xiong, Shi, & Xu, [2016](#mgg3801-bib-0049){ref-type="ref"}). *IL‐6* rs1800796, a function variant located in the promoter region of *IL‐6*, has been evaluated for its association with many kinds of diseases, including cancers, celiac disease, chronic HBV infection, acute coronary syndrome, ischemic stroke, periodontitis, IgA nephropathy, hip fracture, osteoarthritis, acute chorioamnionitis, etc., (Akinyemi et al., [2017](#mgg3801-bib-0001){ref-type="ref"}; Amr, El‐Awady, & Raslan, [2016](#mgg3801-bib-0002){ref-type="ref"}; Barartabar et al., [2018](#mgg3801-bib-0003){ref-type="ref"}; Du, Gao, Zhang, & Wang, [2015](#mgg3801-bib-0006){ref-type="ref"}; Eftekhari et al., [2018](#mgg3801-bib-0007){ref-type="ref"}; Fernandes et al., [2015](#mgg3801-bib-0008){ref-type="ref"}; Fragoso et al., [2010](#mgg3801-bib-0010){ref-type="ref"}; Kaditis et al., [2014](#mgg3801-bib-0014){ref-type="ref"}; Konwar, Del Gobbo, Terry, & Robinson, [2019](#mgg3801-bib-0015){ref-type="ref"}; Li et al., [2018](#mgg3801-bib-0021){ref-type="ref"}; Ponce de Leon‐Suarez et al., [2018](#mgg3801-bib-0028){ref-type="ref"}; Tang et al., [2013](#mgg3801-bib-0035){ref-type="ref"}; Wang, Chen, Zhao, Zhang, & Yu, [2014](#mgg3801-bib-0040){ref-type="ref"}; Wang et al., [2016](#mgg3801-bib-0041){ref-type="ref"}; Zhang et al., [2017](#mgg3801-bib-0045){ref-type="ref"}; Zhang, Mao, & Sun, [2015](#mgg3801-bib-0047){ref-type="ref"}; Zhao, Li, & Li, [2019](#mgg3801-bib-0048){ref-type="ref"}). Although two previous studies evaluated the associations of *IL‐6* rs1800796 with the development of OSA, the results were not significant, which may be caused by the relatively small sample size (Kaditis et al., [2014](#mgg3801-bib-0014){ref-type="ref"}; Zhang et al., [2009](#mgg3801-bib-0046){ref-type="ref"}). In our study, we have enough power to identified *VWF* rs1063856 was significantly associated with both the susceptibility and severity of OSA.

*TNF* was significantly higher in OSA patients, and more pronounced with the more severe grades of OSA (Li & Zheng, [2017](#mgg3801-bib-0020){ref-type="ref"}). A meta‐analysis revealed that *TNF* rs1800629 was significantly associated with OSA under an allele frequency model (three studies, odds ratio \[OR\] = 1.82, 95% confidence interval \[CI\] 1.26--2.61). This result was consistent with our findings, although we did not find significant association between *TNF* rs1800629 and the severity of OSA. *CRP* was a crucial inflammatory component of OSA pathophysiology, and meta‐analysis showed that serum *CRP*/hs‐*CRP* levels were discovered to be higher in OSA patients compared with control subjects (Li, Wei, Qin, & Wei, [2017](#mgg3801-bib-0019){ref-type="ref"}). *CRP* rs2794521 has been found to be associated with stroke, coronary heart disease, and preeclampsia (Kotlega et al., [2014](#mgg3801-bib-0016){ref-type="ref"}; Wang et al., [2009](#mgg3801-bib-0039){ref-type="ref"}; Wu, Huang, Huang, & Fan, [2017](#mgg3801-bib-0043){ref-type="ref"}). However, it was not evaluated for OSA. Our results represent the first report of *CRP* rs2794521 in OSA occurrence.

5. CONCLUSIONS {#mgg3801-sec-0016}
==============

In conclusion, we deduced that *VWF* rs1063856, *IL‐6* rs1800796, *TNF* rs1800629, and *CRP* rs2794521 contribute to develop OSA in a Chinese population, while *VWF* rs1063856 and *IL‐6* rs1800796 were associated with the increased severity of OSA. Our study, together with previous studies, would benefit the construction of early warning model, early prevention, and screening of OSA. Our results also provided a new therapeutic target for treatment of OSA. These findings further support that inflammatory cytokines were closely related to the occurrence and development of OSA.
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